Aging,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 19, 2024
In
recent
years,
the
detection
and
analysis
of
circulating
tumor
DNA
(ctDNA)
have
emerged
as
a
new
focus
in
field
cancer
research,
particularly
early
diagnosis
hepatocellular
carcinoma
(HCC)
monitoring
therapeutic
efficacy.
ctDNA,
which
refers
to
cell-free
fragments
released
into
bloodstream
from
cells
upon
cell
death
or
shedding,
carries
tumor-specific
genetic
epigenetic
alterations,
thereby
providing
non-invasive
approach
for
prognosis.
The
concentration
ctDNA
blood
is
higher
compared
that
healthy
individuals
other
liquid
biopsies
early-stage
cancers,
closely
associated
with
comprehensive
sequencing
studies
HCC.
Recent
indicated
sequential
patients
receiving
primary
adjuvant
therapy
HCC
can
detect
treatment
resistance
recurrence
before
visible
morphological
changes
tumor,
making
it
valuable
basis
rapid
adjustment
strategies.
However,
this
technology
continuously
being
optimized
improved.
Challenges
such
enhancing
accuracy
tests,
reducing
burden
high-throughput
on
large
number
samples,
controlling
variables
assessment
relationship
between
burden,
need
be
addressed.
Overall,
despite
existing
challenges,
examination
opened
up
avenues
efficacy
carcinoma,
expanding
horizons
field.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: May 20, 2024
Abstract
Tumor
biomarkers,
the
substances
which
are
produced
by
tumors
or
body’s
responses
to
during
tumorigenesis
and
progression,
have
been
demonstrated
possess
critical
encouraging
value
in
screening
early
diagnosis,
prognosis
prediction,
recurrence
detection,
therapeutic
efficacy
monitoring
of
cancers.
Over
past
decades,
continuous
progress
has
made
exploring
discovering
novel,
sensitive,
specific,
accurate
tumor
significantly
promoted
personalized
medicine
improved
outcomes
cancer
patients,
especially
advances
molecular
biology
technologies
developed
for
detection
biomarkers.
Herein,
we
summarize
discovery
development
including
history
conventional
innovative
used
biomarker
classification
biomarkers
based
on
tissue
origins,
application
clinical
management.
In
particular,
highlight
recent
advancements
biomarker-based
anticancer-targeted
therapies
emerging
as
breakthroughs
promising
strategies.
We
also
discuss
limitations
challenges
that
need
be
addressed
provide
insights
perspectives
turn
into
opportunities
this
field.
Collectively,
multiple
emphasized
review
may
guidance
precision
medicine,
broaden
horizons
future
research
directions,
expedite
patients
according
their
rather
than
organs
origin.
Molecular Cancer,
Journal Year:
2023,
Volume and Issue:
22(1)
Published: Oct. 6, 2023
Abstract
Pancreatic
cancer
(PC)
is
one
of
the
most
common
malignancies.
Surgical
resection
a
potential
curative
approach
for
PC,
but
patients
are
unsuitable
operations
when
at
time
diagnosis.
Even
with
surgery,
some
may
still
experience
tumour
metastasis
during
operation
or
shortly
after
as
precise
prognosis
evaluation
not
always
possible.
If
miss
opportunity
surgery
and
resort
to
chemotherapy,
they
face
challenging
issue
chemotherapy
resistance.
In
recent
years,
liquid
biopsy
has
shown
promising
prospects
in
disease
diagnosis,
treatment
monitoring,
assessment.
As
noninvasive
detection
method,
offers
advantages
over
traditional
diagnostic
procedures,
such
tissue
biopsy,
terms
both
cost-effectiveness
convenience.
The
information
provided
by
helps
clinical
practitioners
understand
molecular
mechanisms
underlying
occurrence
development,
enabling
formulation
more
personalized
decisions
each
patient.
This
review
introduces
biomarkers
methods
including
circulating
cells
(CTCs),
DNA
(ctDNA),
noncoding
RNAs
(ncRNAs),
extracellular
vesicles
(EVs)
exosomes.
Additionally,
we
summarize
applications
early
response,
resistance
assessment,
prognostic
PC.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2024,
Volume and Issue:
43(1)
Published: April 1, 2024
Abstract
Lung
cancer
stands
as
the
most
prevalent
form
of
globally,
posing
a
significant
threat
to
human
well-being.
Due
lack
effective
and
accurate
early
diagnostic
methods,
many
patients
are
diagnosed
with
advanced
lung
cancer.
Although
surgical
resection
is
still
potential
means
eradicating
cancer,
usually
miss
best
chance
for
treatment,
even
after
may
experience
tumor
recurrence.
Additionally,
chemotherapy,
mainstay
treatment
has
be
chemo-resistant,
resulting
in
poor
clinical
outcomes.
The
emergence
liquid
biopsies
garnered
considerable
attention
owing
their
noninvasive
nature
ability
continuous
sampling.
Technological
advancements
have
propelled
circulating
cells
(CTCs),
DNA
(ctDNA),
extracellular
vesicles
(EVs),
metabolites,
tumor-educated
platelets
(TEPs),
tumor-associated
antigens
(TAA)
forefront
key
biopsy
biomarkers,
demonstrating
intriguing
encouraging
results
diagnosis
prognostic
evaluation
This
review
provides
an
overview
molecular
biomarkers
assays
utilized
encompassing
CTCs,
ctDNA,
non-coding
RNA
(ncRNA),
EVs,
TAAs
TEPs.
Furthermore,
we
expound
on
practical
applications
biopsies,
including
diagnosis,
response
monitoring,
evaluation,
recurrence
monitoring
context
Cancers,
Journal Year:
2024,
Volume and Issue:
16(13), P. 2478 - 2478
Published: July 7, 2024
The
rise
of
drug
resistance
in
cancer
cells
presents
a
formidable
challenge
modern
oncology,
necessitating
the
exploration
innovative
therapeutic
strategies.
This
review
investigates
latest
advancements
overcoming
mechanisms
employed
by
cells,
focusing
on
emerging
modalities.
intricate
molecular
insights
into
resistance,
including
genetic
mutations,
efflux
pumps,
altered
signaling
pathways,
and
microenvironmental
influences,
are
discussed.
Furthermore,
promising
avenues
offered
targeted
therapies,
combination
treatments,
immunotherapies,
precision
medicine
approaches
highlighted.
Specifically,
synergistic
effects
combining
traditional
cytotoxic
agents
with
molecularly
inhibitors
to
circumvent
pathways
examined.
Additionally,
evolving
landscape
immunotherapeutic
interventions,
immune
checkpoint
adoptive
cell
is
explored
terms
bolstering
anti-tumor
responses
evasion
mechanisms.
Moreover,
significance
biomarker-driven
strategies
for
predicting
monitoring
treatment
underscored,
thereby
optimizing
outcomes.
For
future
direction
paradigms,
current
focused
prevailing
challenges
improving
patient
outcomes,
through
an
integrative
analysis
these
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(1), P. 30 - 30
Published: Jan. 6, 2025
Extensive
investigation
has
been
conducted
on
plant-based
resources
for
their
pharmacological
usefulness,
including
various
cancer
types.
The
scope
of
this
review
is
wider
than
several
studies
with
a
particular
focus
breast
cancer,
which
an
international
health
concern
while
studying
sources
flavonoids,
carotenoids,
polyphenols,
saponins,
phenolic
compounds,
terpenoids,
and
glycosides
apart
from
focusing
nursing.
Important
findings
prior
are
synthesized
to
explore
these
compounds'
sources,
mechanisms
action,
complementary
synergistic
effects,
associated
side
effects.
It
was
reviewed
that
the
exposure
certain
doses
catechins,
piperlongumine,
lycopene,
isoflavones
cucurbitacinfor
sufficient
period
can
provide
profound
anticancer
benefits
through
biological
events
such
as
cell
cycle
arrest,
cells
undergoing
apoptosis
disruption
signaling
pathways
including,
but
not
limited
JAK-STAT3,
HER2-integrin,
MAPK.
Besides,
study
also
covers
potential
adverse
effects
phytochemicals.
Regarding
mechanisms,
widest
attention
paid
Complementary
strategies
discussed
indicate
it
would
be
realistic
alter
dosage
delivery
systems
liposomes,
nanoparticles,
nanoemulsions,
films
enhance
efficacy.
Future
research
directions
include
refining
approaches,
further
elucidating
molecular
conducting
clinical
trials
validate
findings.
These
efforts
could
significantly
advance
role
phytocompounds
in
management.
Nature Medicine,
Journal Year:
2024,
Volume and Issue:
30(9), P. 2508 - 2516
Published: June 1, 2024
Abstract
Circulating
tumor
DNA
(ctDNA)
is
emerging
as
a
potential
biomarker
in
early-stage
urothelial
cancer,
but
its
utility
metastatic
disease
remains
unknown.
In
the
phase
3
KEYNOTE-361
study,
pembrolizumab
with
and
without
chemotherapy
was
compared
alone
patients
cancer.
The
study
did
not
meet
prespecified
efficacy
thresholds
for
statistical
significance.
To
identify
biomarkers
of
response,
we
retrospectively
evaluated
association
pre-
posttreatment
ctDNA
clinical
outcomes
subset
who
received
(
n
=
130)
or
KEYNOTE-361.
Baseline
associated
best
overall
response
(BOR;
P
0.009),
progression-free
survival
<
0.001)
(OS;
(all;
>
0.05).
Chemotherapy
induced
larger
decreases
from
baseline
to
treatment
cycle
2
than
pembrolizumab;
however,
change
87)
more
BOR
4.39
×
10
−5
)
OS
7.07
102;
BOR:
1.01
−4
;
OS:
0.018).
Tumor
tissue-informed
versions
metrics
were
most
show
statistically
significant
independent
value
explaining
beyond
radiographic
by
RECIST
v.1.1
when
jointly
modeled
(pembrolizumab
0.364;
0.823).
These
results
suggest
distinct
patterns
early
changes
immunotherapy
differences
their
long-term
outcomes,
which
provide
preliminary
insights
into
liquid
biopsies
monitoring
Clinical
trial
registration:
NCT02853305
.
Abstract
Liquid
biopsy
is
regarded
as
a
promising
strategy
for
assisting
precision
medicine
because
of
its
convenience,
noninvasiveness,
and
ability
to
overcome
tumor
heterogeneity
achieve
early
detection.
Recently,
impressive
advancements
in
plasmonic
biosensors,
artificial
intelligence,
portable
Raman
equipment
have
yielded
unprecedented
progress
surface‐enhanced
spectroscopy
(SERS)–based
point‐of‐care
testing
(POCT)
systems
liquid
biopsy.
The
development
these
presents
paradigm
shift
on‐site
applications
by
leveraging
the
unique
benefits
efficiency,
fast
analysis,
portability,
affordability,
user‐friendliness.
Herein,
advances
are
introduced
over
last
3
years
field
SERS‐based
POCT
labeled
label‐free
biomarker
analysis
body
fluids,
including
circulating
proteins
cells,
exosomes,
micro‐RNA,
DNA.
Additionally,
powerful
machine
learning
algorithms
(including
deep
algorithms)
integrated
with
SERS
effectively
extract
potential
data
features
generate
precise
diagnostic
models.
review
highlights
use
handheld
devices
significantly
promoting
application
clinical
scenarios.
Finally,
outlines
challenges
future
perspectives
this
technology.
